AFMD - Affimed shares rise on continuation of REDIRECT study of AFM13 in T-cell cancer

Affimed (AFMD) gains 19% premarket in reaction to its announcement to continue enrollment in the REDIRECT trial, which is evaluating AFM13 as a monotherapy for the treatment of relapsed or refractory CD30-positive peripheral T-cell lymphoma ((PTCL)). The decision to continue the trial followed a preplanned interim futility analysis which was triggered following enrollment of 20 patients in both Cohort A (?10% CD30) and Cohort B (>1% to <10% CD30).The futility analysis demonstrated that the response rate in Cohort A achieved the predefined threshold for continuation of the study.The response rate in Cohort B was sufficiently comparable to allow merging of both cohorts into a single cohort for all patients with CD30 >1%, per the study protocol.Evidence of anti-tumor response was observed in both cohorts with complete and partial responses.The safety analysis was consistent with previously reported data from Affimed’s Phase 1 trials of AFM13. Affimed will host an investor conference call today

For further details see:

Affimed shares rise on continuation of REDIRECT study of AFM13 in T-cell cancer